Literature DB >> 8729149

Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program.

M N Gourevitch1, W Wasserman, M S Panero, P A Selwyn.   

Abstract

Incomplete antituberculous chemoprophylaxis and treatment are major causes of the resurgence of tuberculosis, often drug-resistant, among drug users. We offered directly observed antituberculous chemoprophylaxis (n = 102) or treatment (n = 12) to tuberculous chemoprophylaxis (n = 102) or treatment (n = 12) to eligible methadone maintenance treatment patients. Methadone dosing was not contingent upon ingestion of antituberculous medication(s). No material incentives were provided. Ninety (88%) prophylaxis and 9 (75%) treatment patients were administered > or = 5 weekly doses of antituberculous medications during > or = 80% of 4740 patient-weeks. The majority of patients were HIV-seropositive. Active substance abuse was not associated with diminished adherence. Over 80% of patients completed or were still receiving therapy at the end of the study. Adherence to and completion of directly observed antituberculous therapy can thus be attained by drug users in treatment, despite ongoing drug misuse. Substance abuse treatment programs provide opportunities for enhanced compliance, and should thus be viewed as critical components of strategies to address the tuberculosis epidemic in drug users.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8729149     DOI: 10.1300/J069v15n01_07

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  16 in total

1.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

2.  Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.

Authors:  Kenneth A Harris; Julia H Arnsten; Alain H Litwin
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

Review 3.  Achieving Smoking Cessation Among Persons with Opioid Use Disorder.

Authors:  Cynthia Vlad; Julia H Arnsten; Shadi Nahvi
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 4.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

5.  Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.

Authors:  D C Perlman; M N Gourevitch; C Trinh; N Salomon; L Horn; D C Des Jarlais
Journal:  J Urban Health       Date:  2001-09       Impact factor: 3.671

Review 6.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

7.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

8.  A comparison of modified directly observed therapy to standard care for chronic hepatitis C.

Authors:  Patricia A Cioe; Michael D Stein; Kittichai Promrat; Peter D Friedmann
Journal:  J Community Health       Date:  2013-08

9.  Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine.

Authors:  Olga Morozova; Sergii Dvoryak; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2013-09-09

10.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Authors:  Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2008-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.